The identification of clinical exacerbations in asthma and atopic dermatitis after COVID-19
DOI:
https://doi.org/10.33448/rsd-v11i15.37196Keywords:
Asthma; Atopic dermatitis; Symptom flare up; COVID-19.Abstract
In January 2020, the World Health Organization declared a Public Health Emergency and on March 11, a pandemic. COVID-19 is caused by SARS-CoV-2 and has a clinic characterized with associated acute respiratory symptoms or no systemic symptoms. The cutaneous manifestations of the disease are less reported and its influence on the evolution and diagnosis have been poorly described. Asthma is a heterogeneous condition and exacerbations of the disease occur due to viral infections. Atopic dermatitis is a disease that has increasingly affected the population and with the change in the behavioral routine of people related to the social isolation caused by the pandemic, there were triggers for the aggravation. The present study seeks to evaluate literature data on the potential effect of SARS-CoV-2 infection on atopic dermatitis and asthma in asthmatic, atopic and healthy patients. This is a systematic literature review carried out through the PUBMED platform between May and July 2022, with descriptors “asthma”, “atopic dermatitis”, “symptom flare up” and “COVID-19”, having been selected 11 articles. There was a reduction in asthma exacerbations due to the reduction of environmental triggers, social distancing and greater adherence to the treatment of the disease. On the other hand, there was an increase in exacerbations of atopic dermatitis, showing an association between some stressors and worsening of the course of the disease. Asthmatics do not have an increase in exacerbations when infected with SARS-CoV-2. While patients with atopic dermatitis manifest greater exacerbation.
References
Abrams, E. M., W‘t Jong, G., & Yang, C. L. (2020). Asthma and COVID-19. Cmaj, 192(20), E551-E551.
AAD. (2022). Managing Your Practice through the COVID-19 Outbreak. https://www.aad.org/member/practice/managing/coronavirus.
Asseri, A. A. (2021). Pediatric Asthma Exacerbation in Children with Suspected and Confirmed Coronavirus Disease 2019 (COVID-19): An Observational Study from Saudi Arabia. Journal of asthma and allergy, 14, 1139.
Bakakos, A., Bakakos, P., & Rovina, N. (2021). Unraveling the Relationship of Asthma and COVID-19. Journal of Personalized Medicine, 11(12), 1374.
Bateman, E. D., Hurd, S. S., Barnes, P. J., Bousquet, J., Drazen, J. M., FitzGerald, M., ... & Zar, H. J. (2008). Global strategy for asthma management and prevention: GINA executive summary. European Respiratory Journal, 31(1), 143-178.
Burgdorf, W. H. C., Plewig, G., Wolff, H. H., & Landthaler, M. (2010). Dermatologia Braun-Falco. Lublin, Poland, 513.
Bullrich, M. B., Fridman, S., Mandzia, J. L., Mai, L. M., Khaw, A., Gonzalez, J. C. V., ... & Sposato, L. A. (2020). COVID-19: stroke admissions, emergency department visits, and prevention clinic referrals. Canadian Journal of Neurological Sciences, 47(5), 693-696.
Carli, G., Cecchi, L., Stebbing, J., Parronchi, P., & Farsi, A. (2021). Is asthma protective against COVID‐19? Allergy, 76(3), 866.
Chan, K. P. F., Kwok, W. C., Ma, T. F., Hui, C. H., Tam, T. C. C., Wang, J. K. L., ... & Ho, P. L. (2021). Territory-Wide study on hospital admissions for asthma exacerbations in the COVID-19 pandemic. Annals of the American Thoracic Society, 18(10), 1624-1633.
Collaboration for Environmental Evidence. (2013). Guidelines for systematic review and evidence synthesis in environmental management. Environmental Evidence, 4, 1-82
Dattola, A., Bennardo, L., Silvestri, M., & Nisticò, S. P. (2019). What's new in the treatment of atopic dermatitis?. Dermatologic Therapy, 32(2), e12787.
De Boer, G., Braunstahl, G. J., Hendriks, R., & Tramper-Stranders, G. (2021). Asthma exacerbation prevalence during the COVID-19 lockdown in a moderate-severe asthma cohort. BMJ open respiratory research, 8(1), e000758.
Filgueiras, J. C., & Hippert, M. I. S. (1999). A polêmica em torno do conceito de estresse. Psicologia: ciência e profissão, 19, 40-51.
Garcia-Pachon, E., Ruiz-Alcaraz, S., Baeza-Martinez, C., Zamora-Molina, L., Soler-Sempere, M. J., Padilla-Navas, I., & Grau-Delgado, J. (2021). Symptoms in patients with asthma infected by SARS-CoV-2. Respiratory Medicine, 185, 106495.
Garg, S., Kim, L., Whitaker, M., O’Halloran, A., Cummings, C., Holstein, R., ... & Fry, A. (2020). Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed coronavirus disease 2019—COVID-NET, 14 States, March 1–30, 2020. Morbidity and mortality weekly report, 69(15), 458.
Gil, C. (2002). Como elaborar projetos de pesquisa. Atlas.
Guan, W. J., Liang, W. H., Zhao, Y., Liang, H. R., Chen, Z. S., Li, Y. M., ... & He, J. X. (2020). Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. European Respiratory Journal, 55(5).
Hurst, J. H., Zhao, C., Fitzpatrick, N. S., Goldstein, B. A., & Lang, J. E. (2021). Reduced pediatric urgent asthma utilization and exacerbations during the COVID‐19 pandemic. Pediatric pulmonology, 56(10), 3166-3173.
Jackson, D. J., Busse, W. W., Bacharier, L. B., Kattan, M., O’Connor, G. T., Wood, R. A., ... & Altman, M. C. (2020). Association of respiratory allergy, asthma, and expression of the SARS-CoV-2 receptor ACE2. Journal of Allergy and Clinical Immunology, 146(1), 203-206.
Kennedy, J. L., Pham, S., & Borish, L. (2019). Rhinovirus and asthma exacerbations. Immunology and Allergy Clinics, 39(3), 335-344.
Kimyai-Asadi, A., & Usman, A. (2001). The role of psychological stress in skin disease. Journal of cutaneous medicine and surgery, 5(2), 140-145.
Kimura, H., Francisco, D., Conway, M., Martinez, F. D., Vercelli, D., Polverino, F., ... & Kraft, M. (2020). Type 2 inflammation modulates ACE2 and TMPRSS2 in airway epithelial cells. Journal of Allergy and Clinical Immunology, 146(1), 80-88.
Lada, G., Talbot, P. S., Bewley, A., & Kleyn, C. E. (2020). Mental health and dermatology practice in the COVID‐19 pandemic. Clinical and Experimental Dermatology.
Liu, S., Zhi, Y., & Ying, S. (2020). COVID-19 and asthma: reflection during the pandemic. Clinical reviews in allergy & immunology, 59(1), 78-88.
Mangini, C. S. M., Vasconcelos, R. C. F. D., Rodriguez, E. V. R., & Oliveira, I. R. L. D. (2022). Social isolation: main dermatosis and the impact of stress during the COVID-19 pandemic. Einstein (São Paulo), 20.
Mikhail, I., & Grayson, M. H. (2019). Asthma and viral infections: An intricate relationship. Annals of Allergy, Asthma & Immunology, 123(4), 352-358.
Miodońska, M., Bogacz, A., Mróz, M., Mućka, S., & Bożek, A. (2021). The effect of SARS-CoV-2 virus infection on the course of atopic dermatitis in patients. Medicina, 57(6), 521.
Pourani, M. R., Ganji, R., Dashti, T., Dadkhahfar, S., Gheisari, M., Abdollahimajd, F., & Dadras, M. S. (2022). [Artículo traducido] Impacto de la pandemia de COVID-19 en los pacientes con dermatitis atópica. Actas Dermo-Sifiliográficas, 113(3), T286-T293.
Sadeghinia, A., & Daneshpazhooh, M. (2021). Immunosuppressive drugs for patients with psoriasis during the COVID‐19 pandemic era. A review. Dermatologic Therapy, 34(1), e14498.
Salciccioli, J. D., She, L., Tulchinsky, A., Rockhold, F., Cardet, J. C., & Israel, E. (2021). Effect of COVID-19 on asthma exacerbation. The Journal of Allergy and Clinical Immunology: In Practice, 9(7), 2896-2899.
Shah, S. G. S., & Farrow, A. (2020). A commentary on “World Health Organization declares global emergency: A review of the 2019 novel Coronavirus (COVID-19)”. International journal of surgery (London, England), 76, 128.
Shah, S. A., Quint, J. K., & Sheikh, A. (2022). Impact of COVID-19 pandemic on asthma exacerbations: Retrospective cohort study of over 500,000 patients in a national English primary care database. The Lancet Regional Health-Europe, 19, 100428.
Shaker, M. S., Oppenheimer, J., Grayson, M., Stukus, D., Hartog, N., Hsieh, E. W., ... & Greenhawt, M. (2020). COVID-19: pandemic contingency planning for the allergy and immunology clinic. The Journal of Allergy and Clinical Immunology: In Practice, 8(5), 1477-1488.
Talamonti, M., Galluzzo, M., Chiricozzi, A., Quaglino, P., Fabbrocini, G., Gisondi, P., ... & PSO-BIO-COVID study group. (2021). Characteristic of chronic plaque psoriasis patients treated with biologics in Italy during the COVID-19 Pandemic: Risk analysis from the PSO-BIO-COVID observational study. Expert Opinion on Biological Therapy, 21(2), 271-277.
Tang, K., Wang, Y., Zhang, H., Zheng, Q., Fang, R., & Sun, Q. (2020). Cutaneous manifestations of the Coronavirus Disease 2019 (COVID‐19): A brief review. Dermatologic therapy, 33(4), e13528.
Taytard, J., Coquelin, F., & Beydon, N. (2021). Improvement in asthma symptoms and pulmonary function in children after SARS-CoV-2 outbreak. Frontiers in Pediatrics, 9.
Velavan, T. P., & Meyer, C. G. (2020). The COVID-19 epidemic. Tropical Medicine & International Health.
World Health Organization. (2020). Overview of public health and social measures in the context of COVID-19: interim guidance, 18 May 2020 (No. WHO/2019-nCoV/PHSM_Overview/2020.1). World Health Organization.
Young, S., & Fernandez, A. P. (2020). Skin manifestations of COVID-19. Cleveland Clinic journal of medicine.
Zhou, P., Yang, X. L., Wang, X. G., Hu, B., Zhang, L., Zhang, W., ... & Shi, Z. L. (2020). A pneumonia outbreak associated with a new coronavirus of probable bat origin. nature, 579(7798), 270-273.
Ziegler, C. G., Allon, S. J., Nyquist, S. K., Mbano, I. M., Miao, V. N., Tzouanas, C. N., ... & Zhang, K. (2020). SARS-CoV-2 receptor ACE2 is an interferon-stimulated gene in human airway epithelial cells and is detected in specific cell subsets across tissues. Cell, 181(5), 1016-1035.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Júlia Silva Almeida de Oliveira; Adriana de Oliveira Guimarães
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
